Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study

By afschroeder • March 14, 2026

Landovitz RJ, Pinedo Y, Hinestrosa F, Crofoot GE, Brinson C, Buchbinder S, Molina JM, Gravett RM, Brock JB, Ramgopal MN, Rosengren AL, Ofotokun I, Valdez Madruga J, Liegeon G, Panchia R, Supparatpinyo K, Avihingsanon A, Creticos C, Swaminathan S, Doblecki-Lewis S, Rodriguez J, Siegel M, Oka S, Puthanakit T, Grinsztejn B, Sanders EJ, Lama JR, Lombaard J, Ndlovu N, Hwang P, Du J, Jackson B, Homony B, Evans B, Sklar P, Robertson MN, Plank RM. Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study. Clin Infect Dis. 2026 Mar 14:ciag171. doi: 10.1093/cid/ciag171. Epub ahead of print. PMID: 41830344.

Tags: cisgender men, HIV-1 prevention, Infectious Diseases, islatravir, PrEP, Publications, Transgender women

The hantavirus question we are not asking

Hensley LE, Halbrook M, Hoff NA, Merritt S, Olinger GG, Skinner B, von Fricken ME, Kindrachuk J, Rimoin AW. The hantavirus question we are not[...]

Advanced HIV Disease at First Diagnosis in South Brazil Extended Beyond Traditionally Targeted Populations: A 10-Year Hospital-Based Study (2015-2024)

Hernandez CJ, Fonseca PM, Noal A, Zywica M, Cambou MC, Varella IRDS, Santos BR, de Melo MG, Nielsen-Saines K. Advanced HIV Disease at First Diagnosis[...]

Does AI know how to choose wisely? Do not trust and definitely verify when using generative AI in stewardship operations

Dora AV, Benjamin LN, Graber CJ, Branch-Elliman W. Does AI know how to choose wisely? Do not trust and definitely verify when using generative AI[...]